[From the aspect of pre-clinical study of new anticancer candidate compounds]

In the pre-clinical study of anticancer candidate compounds, the following three points should be carefully evaluated before decision to enter the clinical trials. Namely, 1) the data on the antitumor efficacies (in vitro and in vivo), 2) animal toxicities and 3) pharmacological studies. Since more attention has been placed on the clinical trials to protect the right of cancer patients, the toxicity data are especially examined carefully using small and large experimental animals. Feasibility to enter in the clinical studies should be examined by above three points in the preclinical studies.